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ABSTRACT
The majority of breast cancers are estrogen receptor positive (ER+). Blockade 
of estrogen biosynthesis by aromatase inhibitors (AIs) is the first-line endocrine 
therapy for post-menopausal women with ER+ breast cancers. However, AI resistance 
remains a major challenge. We have demonstrated previously that increased GDNF/
RET signaling in ER+ breast cancers promotes AI resistance. Here we investigated the 
efficacy of different small molecule RET kinase inhibitors, sunitinib, cabozantinib, NVP-
BBT594 and NVP-AST487, and the potential of combining a RET inhibitor with the AI 
letrozole in ER+ breast cancers. The most effective inhibitor identified, NVP-AST487, 
suppressed GDNF-stimulated RET downstream signaling and 3D tumor spheroid 
growth. Ovariectomized mice were inoculated with ER+ aromatase-overexpressing 
MCF7-AROM1 cells and treated with letrozole, NVP-AST487 or the two drugs in 
combination. Surprisingly, the three treatment regimens showed similar efficacy in 
impairing MCF7-AROM1 tumor growth in vivo. However in vitro, NVP-AST487 was 
superior to letrozole in inhibiting the GDNF-induced motility and tumor spheroid 
growth of MCF7-AROM1 cells and required in combination with letrozole to inhibit 
GDNF-induced motility in BT474-AROM3 aromatase expressing cells. These data 
indicate that inhibiting RET is as effective as the current therapeutic regimen of AI 
therapy but that a combination treatment may delay cancer cell dissemination and 
metastasis.
INTRODUCTION
Endocrine therapies have shown to be effective in 
patients that express estrogen receptor-α (ERα, called 
hereafter ER). However, a significant portion of patients 
display de novo resistance or will develop resistance 
after an initial response. In postmenopausal patients, 
aromatase inhibitors (AIs), which block the conversion 
of androgens to estrogens, are the first-line treatment 
choice [1]. We, along with others, have demonstrated 
previously that a major cause of AI resistance is growth 
factor receptor activation that, via the PI3K/AKT/
mTOR or MAPK pathways, drives ligand-independent 
ER activation [2–6]. These findings have been exploited 
clinically by combining AIs with mTOR [7, 8] or PI3K/
AKT (NCT01437566) [9, 10] inhibitiors.
We have reported that activation of the REarranged 
during Transfection (RET) receptor tyrosine kinase by its 
ligand GDNF decreases response of ER+ breast cancer 
cells to endocrine therapy, including AIs, and that the 
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transcriptional signature of RET downstream signaling 
has both prognostic and predictive value in breast cancer 
[4, 11–13]. Accordingly, the combination of the AI 
letrozole with the RET inhibitor NVP-BBT594 is more 
effective at suppressing GDNF-induced proliferation of 
RET+ ER+ breast cancer cells than either monotherapy 
[12, 14].
In the current study, we first examined in vitro a 
number of small molecule inhibitors known to target 
RET that could be used in combination with an AI 
in vivo. We then chose the most effective inhibitor to 
assess its efficacy when combined with letrozole in an 
in vivo AI-sensitive breast cancer xenograft model.
RESULTS
Impact of different small kinase inhibitors on 
GDNF-induced RET signaling in ER+/RET+ 
MCF7 cells
We have demonstrated that GDNF-dependent RET 
signaling promotes phosphorylation of ER and that, in 
these cells, ER transcriptional activity is blocked by 
siRNA-mediated downregulation of RET expression [4]. 
Further, the inhibitor NVP-BBT594 has been shown to 
impair RET signaling within nanomolar concentrations 
in vitro, however this compound showed toxicity in vivo 
[12]. Consequently, we first compared the efficacy of 
NVP-BBT594 with other small molecule RET inhibitors 
[11]. Three day E2-deprived wild-type MCF7 cells were 
treated with the kinase inhibitors sunitinib (Figure 1A), 
cabozantinib (XL-184) (Figure 1B) and NVP-BBT594 
(Figure 1C) at increasing concentrations and stimulated 
with 20 ng/ml GDNF in presence or absence of E2. 
Since RET has been shown to be an ER-dependent 
gene [14], the presence of E2 in the culture medium 
enhanced RET expression resulting in a stronger 
activation of GDNF-induced RET downstream signaling 
(Figure 1). Of the compounds used, NVP-BBT594 
showed the highest suppression of GDNF-induced 
RET signaling, as assessed by RET, ERK1/2, AKT and 
ER phosphorylation. However, as stated above, NVP-
BBT594 was unsuitable for extending these studies into 
in vivo models due to its in vivo toxicity. Consequently, 
we extended our studies to another RET inhibitor NVP-
AST487, known to be well tolerated by mice [15, 16]. 
Western blot analysis revealed that NVP-AST487 and 
NVP-BBT594 have comparable RET inhibitory activity 
in wild-type MCF7 cells (Figure 2A). Importantly, 
similar results were obtained in MCF7 derivatives with 
stable expression of aromatase, MCF7-AROM1 cells 
(Figure 2B), which provides a model of an AI sensitive 
breast cancer cells. In these experiments, MCF7-
AROM1 cells were deprived of E2 for 3 days and then 
treated with androstenedione, which is converted into 
estrogen by the aromatase enzyme.
NVP-AST487 reduces GDNF-induced MCF7-
AROM1 cell growth in 3D in vitro assays
Next, we evaluated whether the inhibitory effects 
exerted by NVP-AST487 on MCF7-AROM1 cells alter 
tumor cell growth in two independent physiologically 
relevant in vitro assays. In the first, MCF7-AROM1 cells 
were subjected to a colony formation assay on a layer of 
thick Matrigel (Figure 3A, 3B) and in the second, cells 
were grown as three dimensional (3D) tumor spheroids 
in non-adherent conditions (Figure 3C-3E). In both 
settings, MCF7-AROM1 cells were stimulated with 
androstenedione in the presence or absence of GDNF, 
NVP-AST487 and/or letrozole. When plated onto thick 
Matrigel, GDNF-stimulated MCF7-AROM1 cells formed 
a significantly larger number of colonies than vehicle 
treated cells. Importantly, NVP-AST487 treatment was 
more effective than letrozole at blocking the GDNF-
mediated increase in colony formation. Comparable 
results were obtained in the tumor spheroid formation 
assay (Figure 3C-3E). Indeed, both the cell viability 
(Figure 3C) and the size of tumor spheres (Figure 3D) 
were significantly increased by GDNF treatment and this 
GDNF-mediated increase was fully blocked by NVP-
AST487 treatment. In contrast, treatment with letrozole 
was only partially effective in impairing these GDNF-
induced effects, suggesting that in a GDNF-enriched 
microenvironment (i.e. an environment enriched in 
GDNF secreting stromal cells [17, 18]) endocrine therapy 
alone may not be sufficient to impair RET-dependent 
tumor growth. We therefore evaluated if a combinatory 
therapeutic approach was of relevance in an in vivo setting.
Combinatory treatment of NVP-AST487 and 
letrozole is not superior to monotherapies in 
reducing primary tumor growth
MCF7-AROM1 cells were injected subcutaneously 
into immunocompromised mice where they formed 
tumors under androstenedione support, due to aromatase-
mediated conversion into estrogen. Tumor-bearing mice 
were treated with AI letrozole, NVP-AST487 or the 
combination and sacrificed after three weeks (Figure 4A). 
NVP-AST487, either when administered alone or in 
combination with letrozole, clearly impaired the RET 
signaling pathway as monitored by the reduction in RET 
protein levels and a decrease in AKT phosphorylation 
(Figure 4B). Importantly, ERK phosphorylation was 
moderately suppressed by NVP-AST487, highlighting 
a discrepancy between the in vitro and the in vivo 
experimental settings, potentially due to other RET-
independent ERK activating signaling pathways 
activated by the tumor microenvironment inputs. The 
decrease in RET protein levels induced by NVP-
AST487 treatment was also confirmed at cellular level 
by immunohistochemistry, indicating that NVP-AST487 
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was able to access the RET+ cell compartment of the 
tumor (Figure 4C and Supplementary Figures S1 and S2). 
Moreover, NVP-AST487 treatment alone impaired tumor 
growth. In these experiments it is important to note that 
there was no exogenous GDNF treatment indicating that 
in an in vivo setting RET signaling is active in these ER+ 
breast cancer xenografts. In contrast to results obtained in 
3D in vitro assays, RET inhibition and letrozole treatment 
as monotherapies showed comparable effects in impairing 
xenograft growth and, moreover, the combination of NVP-
AST487 and letrozole had no additional effect on tumor 
growth (Figure 4A).
These results are consistent with those obtained by 
Gattelli et al., using a RET+ syngeneic xenograft model 
of J110 mouse mammary tumor cells in FVB mice. J110 
tumor-bearing mice were treated with the NVP-AST487 
inhibitor in the presence or absence of fulvestrant, an 
endocrine therapy that acts by targeting ER for degradation 
[16]. Again, the monotherapies had comparable effects 
in reducing primary tumor growth, but there was no 
enhanced effect when the two compounds were used in 
combination. Taken together these two studies, using 
distinct in vivo breast cancer models, indicate that RET 
signaling in tumor cells in vivo promotes tumor growth. 
Figure 1: NVP-BBT594 impairs RET downstream signaling at nanomolar concentrations in a dose dependent manner. 
Wild-type MCF7 cells were grown in complete medium (E2+) or in E2-deprived DCC medium (E2-) for 3 days, serum-starved for the last 
24 hours and pre-treated with the indicated concentrations of A. sunitinib, B. cabozantinib, or C. NVP-BBT594 for 90 minutes before 30 
minutes GDNF (20 ng/ml) stimulation. Total cell lysates were subjected to western blotting using the indicated antibodies. Tubulin was 
used as a loading control. Molecular size markers are in kDa.
Oncotarget4www.impactjournals.com/oncotarget
Figure 2: NVP-BBT594 and NVP-AST487 have comparable inhibitory effects on RET downstream signaling in both 
wild-type and aromatase-expressing (AROM1) MCF7 cells. A. Wild-type MCF7 cells were serum-starved for 24 hours before 
pre-treating with NVP-AST487 or NVP-BBT594 for 90 minutes before GDNF (20 ng/ml) stimulation for 30 minutes. For the experiments 
performed in the absence of E2, wild-type MCF7 cells were 3 day E2 deprived in DCC medium before serum starvation. B. MCF7-AROM1 
cells were E2 deprived for 3 days in DCC medium and stimulated with androstenedione (10 mM) for the last 24 hours. The cells were then 
serum-starved for a further 24 hours and pre-treated with the indicated concentrations of NVP-AST487 or NVP-BBT594 for 90 minutes 
before GDNF (20 ng/ml) stimulation for 30 minutes. Total cell lysates were subjected to western blotting using the indicated antibodies. 
Tubulin was used as a loading control. Molecular size markers are in kDa.
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Furthermore, inhibiting either RET signaling or ER 
signaling (either by blocking E2 production or promoting 
ER degradation) is comparable in reducing primary tumor 
growth. However, in the Gattelli study, RET inhibition 
combined with fulvestrant treatment led to a significant 
reduction in spontaneous metastasis, compared to either 
treatment alone [16].
NVP-AST487, but not letrozole, blocks GDNF-
induced MCF7-AROM1 cell migration
Since MCF7-AROM1 cells do not spontaneously 
metastasize in mice, we could not directly assess 
the ability of NVP-AST487 to impair metastatic 
dissemination. Therefore, we investigated the effect of 
Figure 3: NVP-AST487 reduces GDNF-induced MCF7-AROM1 cell growth in 3D in vitro assays. MCF7-AROM1 cells 
deprived of E2 for 3 days in DCC medium were stimulated with 10 nM androstenedione and then maintained with or without GDNF 
(20 ng/ml) in the presence or absence of NVP-AST487 (100 nM) and/or letrozole (100 nM) as indicated. Cells were subjected to A, B. 
colony formation assays on Matrigel (10 days), C. cell viability assay (6 days) or D. spheroid formation assays performed in non-adherent 
conditions (6 days). Data represent mean +SEM, n=3 independent experiments. (A) Two-way ANOVA, Bonferroni corrected ***, P<0.001. 
(B) Representative pictures of the assay described in A. Scale bar, 1 mm. C and D, One-way ANOVA; Bonferroni corrected; **, P<0.01; 
***, P<0.001. E. Representative phase contrast images of spheres quantified in D. Scale bar: 400 μM.
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NVP-AST487 on MCF7-AROM1 cells motility in vitro, 
using the Boyden chambers assay. Treatment with GDNF 
resulted in a significant increase in MCF7-AROM1 cell 
motility. Inhibition of aromatase activity with letrozole 
had no inhibitory effect on the migration of GDNF-treated 
cells, but this enhanced cell motility was fully reverted 
by NVP-AST487 treatment (Figure 5A). Importantly, in 
the time-frame of the cell migration experiments, neither 
monotherapies nor combination treatment impaired 
cell viability in 2D culture (Figure 5B) or increased cell 
apoptosis (Figure 5C), indicating that the reduction in cell 
motility observed in the presence of NVP-AST487 was 
due to direct inhibition of RET. These data were confirmed 
in an additional cell line, the ER+/HER2+ aromatase-
expressing BT474-AROM3 cells. These RET-positive 
cells express 1-log lower levels of the RET co-receptor 
GFRα1 when compared to MCF7 cells (not shown) and, 
importantly, GFRα1 levels are influenced by letrozole 
addition (Supplementary Figure S3). Consequently, 
soluble GFRα1 was added for optimal GDNF-induced 
RET signaling activation (Supplementary Figure S3) as 
previously described [12]. In Transwell migration assays, 
GDNF-induced RET activation resulted in a significant 
increase in BT474-AROM3 cell motility (Figure 5D), 
which was blocked to a similar extent by both letrozole 
and NVP-AST487 treatment. Importantly, combining 
the two compounds resulted in a greater inhibition of 
GDNF-induced BT474-AROM3 cell motility (One-way 
ANOVA, Bonferroni’s corrected, P<0.05; Figure 5D), 
without significantly impairing cell viability (Figure 5E) 
or promoting apoptosis (Figure 5F).
DISCUSSION
In this study, we demonstrate that NVP-AST487 
and NVP-BBT594 have comparable potencies as 
inhibitors of GDNF-induced RET signaling in ER+ 
breast cancer cells in vitro. NVP-AST487 was chosen 
Figure 4: Combination treatment of NVP-AST487 and letrozole is not superior to monotherapies in reducing 
primary tumor growth. Ovariectomized mice under androstenedione support were inoculated with MCF7-AROM1 cells. Following 
randomization, mice were treated daily with vehicle, letrozole, NVP-AST487 or letrozole plus NVP-AST487 as described in the Methods 
(n = 10 mice per group). A. Tumor volumes show as fold change relative to day 1 of treatment +SEM (2-way ANOVA, Tukey’s corrected; 
**, P<0.01, ***, P<0.001). At the end of the experiment, tumors were halved for B. extraction of total lysates (n = 3 tumors per treatment 
group) for western blotting as indicated. GAPDH was used as a loading control. Molecular size markers are in kDa. Dotted line indicate 
two separate gels, run in parallel and exposed for equal lengths of time and C. RET immunohistochemistry. Representative images are 
shown. Scale bar, 200 μm.
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Figure 5: NVP-AST487, but not letrozole, reduces GDNF-induced MCF7-AROM1 cell motility. MCF7-AROM1 (A-C) 
and BT474-AROM3 (D-F) cells deprived of E2 for 3 days in DCC medium were stimulated with androstenedione (10 nM) in the presence 
or absence of letrozole (100 nM), GFRα1 (100 ng/ml), GDNF (20 ng/ml) and/or NVP-AST487 (100 nM). (A, D) Cell motility in Transwells 
was measured after 48 hours. One-way ANOVA, Bonferroni’s corrected, **, P<0.01, ***, P<0.001. Representative images of DiffQuick 
strained Transwell filters are shown. 4X magnification. (B, E) Cell viability was measured after 48 hours. Data represent mean +SEM, 
n=3 independent experiments. One-way ANOVA, Bonferroni’s corrected, ns: not significant. (C, F) Apoptosis was measured using the PI/
AnnexinV assay. Bar graphs show mean percentage +SEM of cells that are alive, undergoing early or late apoptosis and cells that are dead. 
One-way ANOVA revealed no significant differences between the groups.
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for in vivo validation as it has a superior safety profile 
in mice. Notably, we show that suppressing GDNF/
RET signaling in vivo with NVP-AST487 is comparable 
in efficacy to AI treatment, the standard of care for 
postmenopausal ER+ breast cancer that is modeled in 
this experimental setting.
Breast cancer cells can escape the inhibitory 
effects of endocrine therapies by increasing ER activity 
independently of estrogen [5]. We, along with others, have 
reported that the receptor tyrosine kinase RET plays an 
important role in endocrine therapies resistance in ER+ 
breast cancer cells by promoting ER phosphorylation, cell 
proliferation, and cell survival [4, 11, 12, 16]. Further, 
it has been recently demonstrated that RET expression 
and activation may also be physiologically relevant 
in triple negative (negative for ER, progesterone and 
HER2 receptor expression) [19] and HER2 positive 
breast cancers [19, 20]. Interestingly, derivatives of the 
cytotoxic agent maytansine, a microtubule-interfering 
drug, conjugated to an anti-RET antibody show dose-
dependent antitumor activity in RET expressing breast 
cancer xenograft models [20]. However, RET is expressed 
in the adult peripheral nervous system and treatment with 
this agent is also associated with on-target neuropathy. As 
a consequence, there remains a need for selective RET 
inhibitors that could be of potential clinical application 
in breast cancer but with reduced toxicity. Encouraging 
data has come from treating in vivo breast cancer patient-
derived xenografts (PDXs) with the small kinase inhibitor 
vandetanib [19]. Although vandetanib reduced RET 
activation and promoted tumor regression in a subset of 
PDXs, it is important to note that this inhibitor also targets 
other tyrosine kinases, in particular VEGFR and EGFR, 
and that vandetanib induced an anti-angiogenic response 
in all PDX tumors independent of their RET or EGFR 
expression levels.
Since RET expression and activation is associated 
with endocrine therapy resistance, there is a rationale 
for combining endocrine agents with RET inhibitors. 
Spanheimer and coworkers have recently reported that 
the selective ER antagonist tamoxifen and vandetanib had 
comparable efficacy in reducing MCF7 tumor growth in 
in vivo. Furthermore, combining the two compounds was 
significantly more effective in reducing tumor growth than 
either agent alone [21]. However, this result is discordant 
with that of Gattelli and coworkers who investigated the 
effects of combining a RET inhibitor with endocrine 
therapy in vivo using the J110 breast cancer murine model 
[16]. They reported in J110 xenografts, no additive effect 
of combining a RET inhibitor with either fulvestrant or 
tamoxifen [16], consistent with the findings reported here 
using an AI-sensitive human xenograft model. Importantly, 
in the J110 model the authors reported a strong effect of 
the RET inhibition on reducing metastatic dissemination, 
particularly when combined with fulvestrant or tamoxifen, 
indicating that RET activation can both promote tumor 
growth and represent an important requirement for J110 
tumor cell dissemination.
In the current study, we demonstrate that, as 
previously reported [22, 23], MCF7-AROM1 xenografts 
are sensitive to the AI letrozole. In this experiment, it 
is notable that the concentration of letrozole used (i.e. 
1 mg/kg/day) slowed tumor growth. However, the same 
concentration in alternative letrozole-sensitive ER+ 
xenograft model was sufficient to induce complete tumor 
remission [24]. These differences may be due to the 
different cell models used, different levels of aromatase 
expression and/or to a different androgen-dependency that 
these models may display.
Since MCF7-AROM1 cells do not form metastases 
in mice, we could not directly assess the ability of NVP-
AST487 to impair metastatic dissemination in when used 
in combination with an AI. However, it was striking that 
in in vitro cell migration assays, treatment with letrozole 
alone had no inhibitory effect on GDNF-induced MCF7-
AROM1 cell motility whereas NVP-AST487 treatment 
resulted in an effective impairment. Interestingly, in an 
alternative model, letrozole treatment reduced BT474-
AROM3 cell motility but full blockade was achieved only 
by combining the RET inhibitor and letrozole.
In summary, the data presented support the 
hypothesis that RET inhibitors, such as NVP-AST487, 
could both impair primary tumor growth and tumor 
dissemination, thereby providing a potential therapeutic 
advantage when used in combination with AIs in post-
menopausal ER+ breast cancers.
MATERIALS AND METHODS
Cell lines and assay
All cell lines were STR (PCR/short tandem repeat) 
profiled by DNA Diagnostic Centre (DCC, London, 
UK). Wild-type MCF7 human breast cancer cells were 
maintained in phenol red-free RPMI 1640 supplemented 
with 10% fetal bovine serum (FBS, Euroclone), 2 mM 
glutamine, and 1 nM 17-β estradiol (E2, Sigma). MCF7 
cells expressing full-length human aromatase MCF7-
AROM1 [22] were employed as a model of AI-sensitive 
cells, and maintained in DMEM supplemented with 
10% FBS, 2 mM L-glutamine, and 1 mg/mL Geniticin/
G418 (Invitrogen). For estrogen deprivation, wild-
type or AROM1 MCF7 and BT474-AROM3 cells 
were cultured for 3 days in phenol red-free RPMI-1640 
medium plus 10% dextran charcoal-treated (DCC) FBS 
and 2 mM glutamine (DCC medium). After 72 h, MCF7-
AROM1 and BT474-AROM3 cells were treated with 
10 nM of androstenedione (Sigma), which is converted 
into estrogens by aromatase, and after 24 h with the AI 
letrozole (Sigma). Cell viability, Western blot analysis, 
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3D colony forming and Annexin V/PI apoptosis assays 
were as previously reported [4, 12, 25].
Compounds
NVP-AST487 (N-[4-[(4-ethyl-1-piperazinyl)methyl]-
3-(trifluoromethyl)phenyl]-N'-[4-[[6-(methylamino)-
4-pyrimidinyl]oxy]phenyl]-urea) and NVP-BBT594 
(5-[[6-(acetylamino)-4-pyrimidinyl]oxy]-2,3-dihydro-N-[4-[(4- 
methyl-1-piperazinyl) methyl]-3-(trifluoromethyl)phenyl]-
1H-indole-1-carboxamide) were provided by Novartis 
Pharmaceuticals, Basel (Switzerland). Cabozantinib and 
sunitinib were purchased from Tocris Bioscience.
Tumor spheroids growth assay
1 × 103 MCF7-AROM1 cells per well were seeded 
in 96-well ultra-low attachment plates in phenol red-free 
RPMI supplemented with 10% DCC FBS and 10 nM 
androstenedione [26]. After 24 hours, assembled spheroids 
were stimulated with 20 ng/ml GDNF (BD Biosciences) 
and treated with 100 nM NVP-AST487 and/or 100 nM 
letrozole. Medium was replaced every 3 days. Spheroid 
growth was monitored by collecting images of the spheroids 
and subsequent size quantification using ImageJ software. 
Cell viability was measured at day 6 with CellTiter-
Glo luminescent assay according to the manufacturer’s 
instructions (Promega, Madison, WI, USA) using a 
Victor 2V Multilabel HTS counter (Wallac-Perkin Elmer, 
Herts, UK).
Colony proliferation assay
Growth factor reduced and phenol red-free 
Matrigel (BD Biosciences, Oxford, UK) was diluted 1:1 
in PBS and 0.2 mL per well was plated into 24-well tissue 
culture dishes and left at 37°C for 2–3 h. Next, 1 × 104 
cells were seeded per well and cultured overnight. The 
following day, cells were stimulated with GDNF (20 ng/
mL) and treated with letrozole, NVP-AST487 or the 
combination as indicated. Medium was replaced every 
3 days and colonies larger than 200 μm were counted at 
day 10.
In vitro transwell motility assay
For motility assay, cells were serum starved 
overnight and seeded into the upper chamber of 8 μm-pore 
Transwells (Corning) in serum-free growth medium, with 
or without the indicated compounds. Cells were allowed 
to migrate towards complete growth medium for 48 hours. 
Non-moving cells were removed mechanically and the 
underside of the Transwells was stained with DiffQuick 
solution (BD Biosciences) as previously reported [27]. 
Chemotaxis was evaluated by counting the cells migrated 
to the lower surface of the filters (six randomly chosen 
fields).
In vivo experiments
MCF7-AROM1 xenografts were established 
as previously described [28]. In brief, 1 × 107 MCF7-
AROM1 cells were inoculated subcutaneously into 
ovariectomized female Ncr Foxhead nude 6- to 
8-week-old mice (Harlan). Throughout the course 
of the experiment, mice were treated daily with 
androstenedione via intradermal injection (100 μg/day). 
Tumors were grown to ~8 mm diameter and then the 
mice were assigned to the following treatment groups. 
All treatments were given daily. Vehicle, 10% N-methyl-
pyrollidone (NMP)/90% polyethylene glycol (PEG300); 
letrozole, 1 mg/kg in 150 μL of 10% NMP/90% PEG300; 
NVP-AST487, 50 mg/kg/d; combination, combination 
of letrozole and NVP-AST487. Tumor growth was 
assessed by caliper measurements of the two largest 
tumor diameters. Volumes were calculated according 
to the formula: a×b2×π/6, where a and b are orthogonal 
tumor diameters. All animal work was carried out with 
UK Home Office approval.
Immunostaining
For RET immunohistochemistry (IHC), antigen 
retrieval was carried out by microwave irradiation for 
5 minutes at full power (900 W) in citrate buffer pH 
6.0. Anti-Ret (E1N8X) XP antibody (Cell Signaling 
technology) was optimized to give robust IHC staining 
of formalin-fixed paraffin-embedded material and was 
applied at 1/100 dilution (see Supplementary Figure S1). 
The stained slides were then scanned on a whole slide 
scanner (Nanozoomer 2.0-HT, Hamamatsu, Japan).
Statistical analysis
Statistical analysis was conducted using GraphPad 
Prism Software as reported in the figure legends and 
Results.
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